Eli Lilly shares fall after slow start for Foundayo weight loss pill

11 articles · Updated · The Wall Street Journal · Apr 24

Foundayo generated about 3,700 U.S. prescriptions in its second week, well below analyst expectations of 8,000 and far behind Novo Nordisk’s Wegovy pill, which had 18,410 prescriptions in its second week.
Eli Lilly’s shares dropped nearly 4% on Friday, while Novo Nordisk’s American depositary receipts rose nearly 6% as investors reacted to the prescription data and competitive dynamics.
Analysts attribute Foundayo’s slower uptake to limited brand recognition compared to Wegovy, whose pill shares a name with its established injection. The weight-loss pill market is expected to see further competition soon.

Is Foundayo's slow start a launch blunder or a strategy to avoid shortages?

Is Foundayo's convenience worth the tradeoff for potentially less weight loss?

Which pill will win: the one with better results or the one that's easier to take?

With insurers blocking prescriptions, will these 'miracle' pills remain out of reach?

How is the food industry preparing for a world with less appetite?

Are weight loss drugs a cure for obesity or a distraction from its root causes?